ScinoPharm to Provide Contract Manufacturing Service for Newly Approved Antidepressant Drug in the United States
TAINAN, Taiwan, Feb. 8, 2011 /PRNewswire-Asia/ — ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.’s Viibryd(TM), a new drug entity recently approved by the United States Food and Drug Administration.
Viibryd is a novel drug for the treatment of adults with major depressive disorder (MDD). The drug’s dual mechanism of action and side effect profile differentiates itself from other antidepressants. Use of Viibryd did not cause significant weight gain or interference with sexual function as seen with some rival drugs.
“ScinoPharm is proud of the fruitful partnership with Clinical Data by being its sole API supplier of vilazodone hydrochloride during Viibryd’s launch. Beginning from process research through timely development and optimization of long and complicated synthetic processes, we have established a win-win partnership,” said Dr. Jo Shen, President and CEO of ScinoPharm.
In relationship similar to the one with Clinical Data, ScinoPharm partners with other leading pharmaceutical companies for custom contract services from clinical materials to commercial. So far the company has handled more than 60 NCE projects, with 4 currently in phase III and 3 having already been approved for launch.
ScinoPharm is set to expand its CRAM services through its new GMP plant in Changshu, China, which is expected to be operational in Q3 2011. The Changshu plant will expand the company’s overall R&D and production capabilities to capture the business opportunities in the rapidly expanding Asian pharmaceutical market.
About ScinoPharm Taiwan
ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. For more information, please visit the Company’s website at www.scinopharm.com.
About Clinical Data, Inc.
Clinical Data’s mission is to develop first-in-class and best-in-category therapeutics. The Company’s lead product, Viibryd, was approved for marketing by the FDA for the treatment of major depressive disorder in adults. The Company is also advancing its late-stage drug candidate, Stedivaze, a pharmacologic stress agent in Phase III development for use during myocardial perfusion imaging. Clinical Data has promising drug candidates entering the clinic in major therapeutic areas including asthma, ophthalmology and diabetes. To learn more, please visit the Company’s website at www.clda.com.
Media Contact: ScinoPharm Taiwan, Ltd. Sabrian Wu TEL: +886-6-508-2869 Mobile Phone: +886-920-056-385 Email: firstname.lastname@example.org
SOURCE ScinoPharm Taiwan, Ltd.